

## WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding GFAT, wherein said antisense compound specifically hybridizes with and inhibits the expression of GFAT.
- 5 2. The antisense compound of claim 1 wherein said GFAT is human GFAT-1.
3. The antisense compound of claim 1 or 2 wherein said antisense compound is an antisense oligonucleotide.
4. The antisense compound of claim 3 wherein said antisense  
10 oligonucleotide comprises at least 8 contiguous nucleic acids of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:3063.
5. The antisense compound of claim 3 wherein said antisense oligonucleotide comprises a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:3063.
- 15 6. The antisense compound of claim 2 wherein said antisense oligonucleotide consists of at least 8 contiguous nucleic acids of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:3063.
7. The antisense compound of claim 2 wherein said antisense oligonucleotide consists of a nucleic acid sequence of SEQ ID NO.1 – SEQ  
20 ID NO:3063.
8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
9. The antisense compound of claim 8 wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 25 10. The antisense compound of claim 2 or 8 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
11. The antisense compound of claim 10 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
12. The antisense compound of claim 2 wherein the antisense  
30 oligonucleotide comprises at least one modified nucleobase.
13. The antisense compound of claim 12 wherein the modified nucleobase is a 5-methylcytosine.

14. The antisense compound of claim 10 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
15. The antisense compound of claim 14 wherein the modified nucleobase is a 5-methylcytosine.
- 5 16. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
17. A composition comprising the antisense compound of claim 2 and a pharmaceutically acceptable carrier or diluent.
18. The composition of claim 17 further comprising a colloidal  
10 dispersion system.
19. A method of inhibiting the expression of mPGES1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 2 so that expression of mPGES-1 is inhibited.
20. A method of treating a human having a disease or condition  
15 associated with mPGES-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 2 so that expression of mPGES-1 is inhibited.
21. The method of claim 20 wherein the disease or condition is arthritis
22. The method of claim 20 wherein the disease or condition is  
20 inflammation
23. The method of claim 20 wherein the disease or condition is pain
24. The method of claim 20 wherein the disease or condition is fever
25. The method of claim 20 wherein the disease or condition is cancer
26. The method of claim 20 wherein the disease or condition is  
25 alzheimer's
27. The method of claim 20 wherein the disease or condition is ophthalmic conditions
28. The method of claim 20 wherein the disease or condition is diabetes.
29. The method of claim 20 wherein the disease or condition is an  
30 immunological disorder.
30. The method of claim 20 wherein the disease or condition is a cardiovascular disorder.

31. The method of claim 20 wherein the disease or condition is a neurologic disorder.
32. The method of claim 20 wherein the disease or condition is ischemia/reperfusion injury.